Starpharma (ASX:SPL) share price surges higher on COVID product update

The Starpharma Holdings Limited (ASX:SPL) share price is surging higher on Thursday after releasing an update on its Viraleze product…

| More on:
A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price has been a strong performer on Thursday.

At the time of writing, the dendrimer products developer's shares are up 6% to $1.89.

Why is the Starpharma share price racing higher?

Investors have been buying Starpharma's shares following the release of an update on its Viraleze antiviral nasal spray.

According to the release, the Viraleze antiviral nasal spray is now available for purchase by consumers in Europe via the company's webstore.

This follows the recent launch of Viraleze in the United Kingdom through LloydsPharmacy's 1,400 stores and online business. It is also expected to be available via independent United Kingdom pharmacies later this month.

What is Viraleze?

Viraleze is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013). This is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute.

These antiviral studies were conducted at the renowned Scripps Research Institute in the United States and a number of other specialist virology laboratories.

It isn't just multiple strains of COVID-19 that Viraleze has been demonstrated to have potent antiviral activity. It also has been found to have potent antiviral activity against RSV (respiratory syncytial virus), MERS, and SARS.

Management notes that the antiviral active in Viraleze works by irreversibly blocking coronavirus SARS-CoV-2 'spike' proteins from binding to human airway cells. This forms a physical barrier to respiratory viruses in the nasal cavity and has multiple unique advantages. One of these is its ability to inactivate the virus either before or after exposure.

Starpharma's CEO, Dr Jackie Fairley, commented: "We are delighted to be rolling out Viraleze in Europe following the UK launch. The product has been very well received in the UK, and we hope that Viraleze will provide European consumers with added peace of mind."

"In addition to making Viraleze available direct to consumers in Europe via www.viraleze.co, commercial discussions for distribution continue in parallel. Starpharma is actively engaged in discussions with a variety of organisations in the region, including sporting teams, which have expressed interest in Viraleze," she concluded.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a Garfield kind of Monday for investors.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today

These shares are starting the week in a positive fashion. But why?

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors have been piling into these four ASX 200 stocks this week. Let’s see why.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Bendigo Bank, NextDC, Nuix, and Vulcan Energy shares are rising today

These shares are ending the week on a high. But why?

Read more »

Girl with painted hands.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy Thursday for ASX investors.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why BHP, DroneShield, Lotus Resources, and Nuix shares are pushing higher today

These shares are having a better day than most on Thursday. But why?

Read more »